Efficient, fratricide free non-viral engineering of CD70-targeted CAR NK cells for hematologic and solid tumor immunotherapy - PubMed
3 hours ago
- #CAR NK cells
- #Non-viral engineering
- #CD70 targeting
- Non-viral engineering of CD70-targeted CAR NK cells using the TcBuster transposon system, combined with CRISPR-Cas9 knockout of CD70 to prevent fratricide.
- Engineered CD70 CAR NK cells show improved efficacy against acute myeloid leukemia (AML) and renal cell carcinoma (RCC) in in vitro and in vivo models.
- Incorporating soluble IL-15 cytokine armoring enhances survival and expansion of CAR NK cells in vivo.
- This method offers a cost-effective and clinically scalable approach for adoptive cell therapy against hematologic and solid tumors.
- The study highlights potential safety advantages of NK cells over T cells and addresses limitations in potency and persistence.